Joel Hetzer

435 total citations
17 papers, 326 citations indexed

About

Joel Hetzer is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Joel Hetzer has authored 17 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 7 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Joel Hetzer's work include Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). Joel Hetzer is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). Joel Hetzer collaborates with scholars based in United States, United Kingdom and Italy. Joel Hetzer's co-authors include Eric Laille, Barry Skikne, Bart L. Scott, Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle, Tao Shi, Kyle J. MacBeth, Sergio Giralt and Basem M. William and has published in prestigious journals such as Blood, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Joel Hetzer

15 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel Hetzer United States 8 292 143 69 57 28 17 326
Naoki Shingai Japan 10 174 0.6× 46 0.3× 36 0.5× 43 0.8× 34 1.2× 29 229
Anna Ravn Landtblom Sweden 7 309 1.1× 271 1.9× 140 2.0× 55 1.0× 26 0.9× 12 386
Fryderyk Lorenz Sweden 10 193 0.7× 66 0.5× 79 1.1× 27 0.5× 15 0.5× 18 239
Magdalena Sierra Spain 7 135 0.5× 126 0.9× 64 0.9× 19 0.3× 70 2.5× 14 236
Min Ruan China 8 185 0.6× 96 0.7× 29 0.4× 86 1.5× 71 2.5× 66 303
Annalisa Paviglianiti Spain 10 155 0.5× 58 0.4× 28 0.4× 36 0.6× 80 2.9× 39 250
Fengkuan Yu China 7 222 0.8× 104 0.7× 67 1.0× 73 1.3× 32 1.1× 25 265
Jinsong Jia China 12 280 1.0× 91 0.6× 75 1.1× 90 1.6× 67 2.4× 39 321
G. Zeile Germany 5 366 1.3× 105 0.7× 73 1.1× 107 1.9× 85 3.0× 6 410
Véronique Harrivel France 8 115 0.4× 39 0.3× 59 0.9× 34 0.6× 34 1.2× 17 170

Countries citing papers authored by Joel Hetzer

Since Specialization
Citations

This map shows the geographic impact of Joel Hetzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Hetzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Hetzer more than expected).

Fields of papers citing papers by Joel Hetzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Hetzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Hetzer. The network helps show where Joel Hetzer may publish in the future.

Co-authorship network of co-authors of Joel Hetzer

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Hetzer. A scholar is included among the top collaborators of Joel Hetzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Hetzer. Joel Hetzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Giugliani, Roberto, Antonio González‐Meneses, Maurizio Scarpa, et al.. (2024). Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program. Orphanet Journal of Rare Diseases. 19(1). 189–189.
2.
Giugliani, Roberto, Christina Grant, Maurizio Scarpa, et al.. (2023). Vestronidase alfa for the treatment of mucopolysaccharidosis type VII (MPS VII): Updated results from a novel, longitudinal, multicenter Disease Monitoring Program (DMP). Molecular Genetics and Metabolism. 138(2). 107117–107117.
3.
Weber, Thomas J., Erik A. Imel, Thomas O. Carpenter, et al.. (2022). Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 108(1). 155–165. 14 indexed citations
4.
Lima, Marcos de, Betül Oran, Richard E. Champlin, et al.. (2018). CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation. 24(10). 2017–2024. 115 indexed citations
5.
Garcia‐Manero, Guillermo, Bart L. Scott, Christopher R. Cogle, et al.. (2018). CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research. 72. 79–85. 15 indexed citations
6.
7.
Garcia‐Manero, Guillermo, Michael R. Savona, Steven D. Gore, et al.. (2016). CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. Blood. 128(22). 905–905. 5 indexed citations
8.
Lima, Marcos de, Betül Oran, Esperanza B. Papadopoulos, et al.. (2016). CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). Biology of Blood and Marrow Transplantation. 22(3). S312–S313. 5 indexed citations
9.
Laille, Eric, Tao Shi, Guillermo Garcia‐Manero, et al.. (2015). Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS ONE. 10(8). e0135520–e0135520. 48 indexed citations
10.
Garcia‐Manero, Guillermo, Steven D. Gore, Suman Kambhampati, et al.. (2015). Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 30(4). 889–896. 86 indexed citations
11.
Savona, Michael R., Steven D. Gore, Kathryn S. Kolibaba, et al.. (2015). CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML). Blood. 126(23). 452–452. 8 indexed citations
12.
García-Manero, G., Michael R. Savona, Christopher R. Cogle, et al.. (2015). 99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS). Leukemia Research. 39. S50–S51. 1 indexed citations
13.
14.
Seymour, John F., John M. Bennett, Alan F. List, et al.. (2014). Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. British Journal of Haematology. 165(1). 49–56. 8 indexed citations
15.
Garcia‐Manero, Guillermo, Michael R. Savona, Steven D. Gore, et al.. (2013). Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS). Blood. 122(21). 1554–1554. 4 indexed citations
16.
17.
Garcia‐Manero, Guillermo, Steven D. Gore, Suman Kambhampati, et al.. (2012). Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. Blood. 120(21). 424–424. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoki Shingai Breakdown of academic impact, for papers by Anna Ravn Landtblom Breakdown of academic impact, for papers by Fryderyk Lorenz Breakdown of academic impact, for papers by Magdalena Sierra Breakdown of academic impact, for papers by Min Ruan Breakdown of academic impact, for papers by Annalisa Paviglianiti Breakdown of academic impact, for papers by Fengkuan Yu Breakdown of academic impact, for papers by Jinsong Jia Breakdown of academic impact, for papers by G. Zeile Breakdown of academic impact, for papers by Véronique Harrivel
Rankless by CCL
2026